Eli Lilly and Company $LLY Shares Acquired by Successful Portfolios LLC

Successful Portfolios LLC grew its position in Eli Lilly and Company (NYSE:LLY) by 2.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,301 shares of the company’s stock after purchasing an additional 32 shares during the quarter. Successful Portfolios LLC’s holdings in Eli Lilly and Company were worth $1,014,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Family CFO Inc acquired a new stake in Eli Lilly and Company during the 2nd quarter worth $54,000. Duquesne Family Office LLC raised its stake in Eli Lilly and Company by 52.5% during the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after acquiring an additional 32,640 shares in the last quarter. Corient IA LLC acquired a new stake in Eli Lilly and Company during the 1st quarter worth $570,000. Cutter Capital Management LP acquired a new stake in Eli Lilly and Company during the 1st quarter worth $14,866,000. Finally, Emerald Advisors LLC raised its stake in Eli Lilly and Company by 60.8% during the 2nd quarter. Emerald Advisors LLC now owns 1,021 shares of the company’s stock worth $796,000 after acquiring an additional 386 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

LLY has been the topic of several research reports. Daiwa America downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Leerink Partners reissued a “market perform” rating and set a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Morgan Stanley lowered their price objective on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a research report on Friday. Wall Street Zen downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 20th. Finally, DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $933.39.

Insiders Place Their Bets

In other news, EVP Daniel Skovronsky bought 1,000 shares of the stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the acquisition, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jamere Jackson acquired 200 shares of the firm’s stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the acquisition, the director owned 9,402 shares of the company’s stock, valued at $6,013,143.12. This represents a 2.17% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 4,514 shares of company stock valued at $2,894,841. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Up 2.5%

Shares of NYSE:LLY opened at $840.46 on Friday. The company has a market cap of $795.47 billion, a price-to-earnings ratio of 54.93, a PEG ratio of 1.14 and a beta of 0.47. The firm’s 50-day simple moving average is $734.60 and its 200-day simple moving average is $766.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.